Prostate cancer is the most common cancer in men and the second largest cancer killer. Yet it presents a unique clinical challenge.
Prostate cancer is highly heterogeneous in both composition and progression—ranging from indolent disease that may never require treatment to aggressive forms demanding immediate intervention.
The critical question: Which patients have disease that will progress and require treatment? The goal is to avoid over-treatment while ensuring timely intervention for those who need it.
Safe avoidance of treatment benefits patients, clinicians, and healthcare systems alike.
Traditional bulk tissue analysis blends all cell types together like a smoothie—losing the proportions of individual cellular components. Deconvolvr unblends the mixture back into its constituent parts, enabling the application of prognostic signatures in tissue compartments that drive disease progression.
By addressing tumor heterogeneity at the cellular level, we enable more accurate prognostic signatures that distinguish aggressive cancers from indolent disease.
20+ years of research experience in prostate, stroma, and cancer markers at UC San Francisco (US), MRC Edinburgh (UK), and McGill University (Canada). Track record in academia, startups (Destina Genomics, Zonula Therapeutics), and technology transfer (Edinburgh Innovations).
Interested in learning more about how Deconvolvr can support prostate cancer research and clinical decision-making?
Contact us at info@dcvr.bio
